FATE — Fate Therapeutics Inc
NASDAQ · Healthcare · Biotechnology
$2.43
+$0.04 (+1.67%)
Fate Therapeutics Inc (FATE) is a biotechnology company listed on NASDAQ. It is led by Bahram Valamehr M.B.A., Ph.D., based in 12278 Scripps Summit Drive, San Diego, CA, United States, 92131, with about 161 employees. Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, FT839, to treat complex autoimmune diseases; and FT825 to treat solid tumors. It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. The company was incorporated in 2007 and is headquartered in San Diego, California.
Latest reported FATE revenue for 2025-09-30 was $1.7M. Net income was -$103.9M. Revenue was down 8.7% from 2025-06-30 to 2025-09-30. FATE currently screens at market cap $331.0M.
Use this FATE page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the FATE quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the FATE SEC filings page. Lician reads the product cache first so this HTML stays unique to Fate Therapeutics Inc even when a live quote feed is slow.
About Fate Therapeutics Inc
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, FT839, to treat complex autoimmune diseases; and FT825 to treat solid tumors. It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. The company was incorporated in 2007 and is headquartered in San Diego, California.
FATE Key Statistics
Market Cap
$331.03M
Volume
709,238
Previous Close
$2.54
Day Range
$2.41 – $2.53
EPS
-$1.64
Revenue
$13.63M
Net Income
-$186.26M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
-78.5%
Profit Margin
-1366.5%
Employees
161
FATE Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $13.63M | $63.53M | $96.30M | $55.85M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$186.26M | -$160.93M | -$281.72M | -$212.15M |
| EPS (Diluted) | -$1.64 | -$1.64 | -$2.91 | -$2.24 |
Total Assets
$440.69M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$36.06M
Operating Cash Flow
-$122.87M
Free Cash Flow
$0.00
Fate Therapeutics Inc Company Information
- President, CEO & Director
- Bahram Valamehr M.B.A., Ph.D.
- Headquarters
- 12278 Scripps Summit Drive, San Diego, CA, United States, 92131
- Website
- www.fatetherapeutics.com
- Phone
- 858 875 1800
- IPO / Founded
- 2013-10-01
- Sector
- Healthcare
- Industry
- Biotechnology